Theresa Visarius
Corporate Officer/Principal chez Immunophotonics, Inc.
Profil
Theresa Visarius is currently the Vice President-International Business Development at Immunophotonics, Inc. She previously worked as the Director-Clinical & Regulatory Affairs at Medyria AG.
She obtained a doctorate degree from the University of Bern.
Postes actifs de Theresa Visarius
| Sociétés | Poste | Début |
|---|---|---|
Immunophotonics, Inc.
 Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Corporate Officer/Principal | - |
Anciens postes connus de Theresa Visarius
| Sociétés | Poste | Fin |
|---|---|---|
Medyria AG
 Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Directeur Technique/Scientifique/R&D | - |
Formation de Theresa Visarius
| University of Bern | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Medyria AG
Medyria AG BiotechnologyHealth Technology Medyria AG develops technologies for endovascular catheter navigation and sensing. Its products include trackcath, flowcath and OEM flow sensor. The firm's technology is a sensor-based system combined with a novel approach for processing flow data and tracking catheters. The targeted medical domains comprise vascular, valve, and heart procedures. The company's products increase accuracy reducing complications and risks, fostering the conversion from open surgery to minimally invasive approach. Medyria was founded by Mauro Massimo Sette in 2012 and is headquartered in Winterthur, Switzerland. | Health Technology |
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
